The European Medicines Company (EMA) has authorised using the Pfizer-BioNTech Covid-19 vaccine for youngsters aged 12 to 15. Pfizer-BioNTech turns into the primary vaccine to be authorised for adolescents within the 27 member states of the European Union (EU), experiences Xinhua information company.
Addressing a press convention right here on Friday, Marco Cavaleri, EMA’s vaccine technique supervisor, mentioned that the medicines’ regulator had obtained the mandatory knowledge to authorise the vaccine for youthful teenagers.
The information reveals that it’s extremely efficient towards Covid-19. He identified that the choice must be authorised by the European Fee and particular person nationwide regulators.
Regulators in Canada and the US had already advisable its use for youngsters. The EMA’s advice was based mostly on a research in additional than 2,200 adolescents within the US exhibiting that the vaccine was secure and efficient.
The trial confirmed that the immune response on this group was similar to that within the 16-25 age group. The research reveals that the vaccine was 100 per cent efficient at stopping Covid, the EMA mentioned in a press release.
The most typical unintended effects in youngsters aged 12 to 15 are much like these in folks aged 16 and above. They embrace ache, tiredness, headache, muscle and joint ache, chills and fever.
Additionally Learn: US, Britain search new WHO look into COVID origins in China
Additionally Learn: UK approves Johnson & Johnson single-dose COVID vaccine